Rules-Based Medicine, Inc. and Psynova Neurotech Announce Companion Diagnostic Collaboration with Roche (JOBS)

AUSTIN, Texas, Dec. 3 /PRNewswire/ -- Rules-Based Medicine, Inc. (RBM) today announced that Psynova Neurotech Limited (Cambridge UK), a majority-owned subsidiary of RBM, has executed an exclusive research and licensing agreement with Roche to collaborate on the discovery, development, validation and commercialization of diagnostic immunoassays to aid the clinical development and commercial differentiation of novel treatments for schizophrenia.

"We are excited to enter into this partnership with Roche," said Dr. Sabine Bahn, chief scientific officer and founder of Psynova. "This alliance is part of an ongoing strategy to leverage the value of our biomarker portfolio in both the development of novel diagnostic aids for physicians and the accelerated development and delivery of novel therapeutics for patients."

About Rules-Based Medicine, Inc.

Rules-Based Medicine, Inc. (RBM) is a CLIA-certified biomarker testing laboratory that solves complex therapeutic development, diagnostic and treatment challenges with innovative products and services. The Company's proprietary multi-analyte profiling (MAP) platform makes the drug discovery and development process more efficient and effective by providing pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins from small sample volumes. Building on the MAP platform, RBM has developed a host of solutions including: (i) a self-contained whole-blood culture system that brings reproducibility and simplicity to ex vivo immune response measurement, (ii) novel and companion diagnostic tests for complex diseases and therapies, (iii) therapeutic-specific MAPs custom designed for late-stage clinical development, and (iv) new assays for the early detection of renal damage. Additional information on RBM is available via the worldwide web at www.rulesbasedmedicine.com.

Rules-Based Medicine, Inc.